Phialogics, a Basel, Switzerland and Heidelberg, Germany-based startup which specializes in the field of autoimmune diseases, raised €600K in Pre-Seed funding.
Backers included High-Tech Gründerfonds.
The company intends to use the funds to further develop its lead candidate in preclinical models in comparison to the current standard of care and other research approaches.
Led by CEO Dr. Andreas Ernst, Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Current lead candidates are genetically engineered monospecific IgVs with the potential to be expanded to bispecific therapeutics to achieve selectivity for inflamed tissue and/or disease-causing immune cells. This strategy has the potential to provide new solutions for patients with autoimmune diseases by rebalancing their overactive immune response in selected organs and tissue.
FinSMEs
05/05/2023